In line with our ongoing expansion and evolving client requirements, Callisto Pharma Group are delighted to announce that they have recently invested in a new Pharmacovigilance database. This investment is as a direct result of our commitment to provide effective solutions to our client’s needs and building a platform for new opportunities and growth. 

Pharmacovigilance obligations are at the forefront of patient safety, and so providing a PV service that allows our clients to easily meet these obligations is crucial. Our database is designed to meet UK and EU standards including including E2B(R3), CIOMS, MedWatch, PSUR and DSUR, with pre-submission case validation and action management and full MedDRA integration.

The new database will introduce efficiencies in reporting and signal detection. As data analysis and signal detection continue to be a priority  for our clients, our database can provide accurate, tailored reporting to both the authorities and our clients, allowing our clients to grow their business, safe in the knowledge that their current portfolio is in good hands. 

The database allows us to scale up our PV services much faster than in the past, ensuring our onboarding is efficient and effective. Our PV database will allow us to support our PV team in delivering a professional and performance driven service to our clients going forward.